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Abstract
Aims To study the effects of intravitreal
bevacizumab (Avastin) on retinal
neovascularization (RN) in patients with
proliferative diabetic retinopathy (PDR).
Methods Retrospective study of patients with
RN due to PDR who were treated with at least
one intravitreal injection of 1.25 or 2.5 mg of
bevacizumab. Patients underwent ETDRS
best-corrected visual acuity (BCVA) testing,
ophthalmoscopic examination, optical
coherence tomography (OCT), and fluorescein
angiography (FA) at baseline and follow-up
visits.
Results Forty-four eyes of 33 patients with
PDR and a mean age of 57.2-years (range: 23–
82 years) participated in the study. Thirty-three
eyes (75%) had previous panretinal
photocoagulation (PRP). Twenty-seven eyes
(61.4%) showed total regression of RN on
fundus examination with absence of
fluorescein leakage, 15 eyes (34.1%)
demonstrated partial regression of RN on
fundus examination and FA. Follow-up had a
mean of 28.4 weeks (range from 24 to 40
weeks). BCVA and OCT demonstrated
improvement (Po0.0001). Three eyes without
previous PRP (‘naive’ eyes) and with vitreous
haemorrhage have avoided vitreo-retinal
surgery. One eye (2.2%) had PDR progression
to tractional retinal detachment requiring
vitrectomy, and one eye (2.2%) had vitreous
haemorrhage with increased intraocular
pressure (ghost cell glaucoma). No systemic
adverse events were observed.
Conclusions Intravitreal bevacizumab
resulted in marked regression of RN in
patients with PDR and previous PRP, and
rapid resolution of vitreous haemorrhage in
three naive eyes. Six-months results of
intravitreal bevacizumab at doses of 1.25 or
2.5 mg in patients with PDR do not reveal any
safety concerns.
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Introduction
Diabetic retinopathy remains a major threat to
sight in the working age population in the
developed world. Furthermore, it is increasing
as a major cause of blindness in other parts of
the world especially in developing countries.1
Proliferative diabetic retinopathy (PDR) is a
major cause of visual loss in diabetic patients. In
PDR, the growth of new vessels from the retina
or optic nerve, is thought to occur as a result of
vascular endothelial grow factor (VEGF) release
into the vitreous cavity as a response to
ischaemia.2–4 Because VEGF has been shown to
play a major role in retinal neovascularization
(RN),2,3 although other factors may be involved
as well,5,6 anti-VEGF treatments have been
hypothesized as an alternative adjunctive
treatment for RN.7,8
Bevacizumab (AvastinTM Genentech Inc., San
Francisco, CA, USA) is a complete full-length
humanized antibody that binds to all subtypes
of VEGF and is successfully used in tumour
therapy as a systemic drug.9 Recent studies
have demonstrated the usefulness of
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an intravitreal injection of bevacizumab in the reduction
of vascular permeability and fibrovascular proliferation
in macular oedema secondary to central vein occlusion,
RN secondary to PDR, and choroidal neovascularization
secondary to age macular degeneration.8,10–14 The
amount of human retinal penetration for a complete
full-length anti-VEGF antibody is not known at present.
However, full thickness retinal penetration of intravitreal
bevacizumab was observed in an animal model.15,16
Additionally, intravitreal bevacizumab does not appear
to be toxic to the albino rabbit retina at a concentration
up to 2.5 mg.17
Panretinal photocoagulation (PRP) currently is the
principal therapy for PDR, unless the patient already has
extensive vitreous haemorrhage, which would preclude
the possibility of laser photocoagulation.
Neovascularization on and around the optic disc
(NVD) and vitreous haemorrhage were found to be
more frequently associated with severe visual loss
despite PRP in the Diabetic Retinopathy Study (DRS) and
Early Treatment Diabetic Retinopathy Study
(ETDRS).18,19 Long intervals between PRP sessions and
the variable amount of time required for a favourable
response may increase the incidence of complications
due to the progression of PDR.18,20 In fact, a single
episode of PRP or shorter intervals between PRP
episodes, although desirable in severe PDR and when the
patient must travel long distances for treatment, are often
associated with acute visual disturbances due to
exudative choroidal detachment, retinal detachment, and
macular oedema.21–24
The purpose of this retrospective study was to evaluate
the effectiveness of intravitreal bevacizumab on RN in
patients with PDR as a base for future studies in which
bevacizumab may be used as an adjuvant treatment to
PRP for PDR.
Patients and methods
We conducted a retrospective study in 44 eyes of 33
patients with RN in patients with PDR, who were treated
with off-label intravitreal bevacizumab between
September 2005 and August 2006 at five institutions in
Venezuela, Costa Rica, Brazil, Argentina, and Peru.
Institutional Review Board/Ethics Committee approval
and patients’ informed consent were obtained for this
study at all five institutions. The off-label use of the drug
and its potential risks and benefits were discussed
extensively with all patients. Eyes that were previously
treated with scatter photocoagulation, had prior focal/
grid laser photocoagulation, and previous intravitreal
triamcinolone injection were included if any of those
therapies had been performed at least 6 months before
intravitreal bevacizumab. An injection of 1.25 mg
(0.05 ml) or 2.5 mg (0.1 ml) of bevacizumab was given
according to the discretion of the treating physician.
Baseline data included age, sex, type, and duration of
diabetes mellitus. Patients also underwent clinical
examination including best-corrected visual acuity
(BCVA) measurement with ETDRS chart, applanation
tonometry, fundus examination, fluorescein angiography
(FA), and optical coherence tomography (OCT). In
patients with clinical significant macular oedema,
baseline central retinal characteristics was observed by
OCT (Stratus III OCT, Carl Zeiss, Dublin, CA, USA) using
six diagonal slow 6-mm radial line scans, with software
versions 3.0 and 4.0, through a dilated pupil by a retina
specialist.
A 0.18-ml aliquot of commercially available
bevacizumab was prepared for each patient and placed
in a tuberculin syringe using aseptic techniques.
Bevacizumab was stored for up to 3 weeks under
refrigeration at 41C under sterile conditions, and the
syringes were capped with a needle. After the eye had
been prepared in a standard manner using 5%
povidone/iodine, an eyelid speculum was used to
stabilize the eyelids, and the injection of 1.25 mg (0.05 ml)
or 2.5 mg (0.1 ml) of bevacizumab was given 3.5–4 mm
posterior to the limbus, through the infero-temporal pars
plana with a 30-gauge needle under topical anaesthesia
or subconjunctival lidocaine. After the injection,
intraocular pressure and retinal artery perfusion were
checked, and patients were instructed to administer
topical antibiotics for 7 days.
Patients were examined at 1, 2 weeks, and 1 month
after the first injection and monthly thereafter. One, three
and six months after initial injection, patient evaluation
was performed using ophthalmic examination with slit-
lamp biomicroscopy, OCT, and FA. Patients were
included in this consecutive series if there was a
minimum of 6-months follow-up. The main outcome
measure was the change in RN defined as the change in
the area of vitreous leakage from NVD and new vessels
elsewhere (NVE) in the late phase of FA. Patients
received reinjections only if RN was not totally resolved
on ophthalmic examination or FA. Data was analysed by
a paired Student’s t-test and a Fisher’s exact test when
appropriate.
Monitored systemic conditions included myocardial
infarction, stroke, systemic hypertension,
thromboembolic diseases, and death. Blood pressure was
measured prior to bevacizumab injection and at 1 and 2
weeks following each injection. Other systemic
conditions were assessed by a thorough review of
systems. If the patients were unable to attend a particular
visit, a telephone interview was conducted to assess for
possible systemic complications, and a new appointment
was scheduled. We certify that all applicable institutional
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and governmental regulations concerning the ethical use
of human volunteers were followed during this research.
Results
We reviewed the clinical records of 33 consecutive
patients (44 eyes) with PDR injected with intravitreal
bevacizumab between September 2005 and August 2006.
Patients had a mean follow-up of 28.4 weeks (range from
24 to 40 weeks). Our patients had a mean age of 57.2
years (range from 23 to 82 years), and 51.5% were female
(16 men and 17 women). Twenty-three diabetic patients
(69.7%) were insulin-dependent. The mean duration of
diabetes was 17 years (range from 1 to 30 years). Thirty-
five eyes (79.5%) were treated with an intravitreal
injection of 2.5 mg of bevacizumab, and nine eyes (20.5%)
with 1.25 mg of bevacizumab. Of the 33 eyes (75%) that
were previously treated with scatter photocoagulation
(Figure 1), 19 had prior focal/grid laser photocoagulation
(Figure 2), and two patients had a previous intravitreal
triamcinolone injection (Table 1). Seventeen eyes had
clinical significant macular oedema (CSME) at
biomicroscopic non-contact fundus examination with a
66- or a 78-D lens.
The mean baseline BCVA was log MAR¼ 1.21 and the
final mean BCVA was log MAR¼ 0.70 (Po0.0001). Final
BCVA analysis by subgroups demonstrated that 12 eyes
(27.3%) remained stable, 29 eyes (65.9%) improved two
or more ETDRS lines of BCVA, and three eyes (6.8%)
decreased two or more ETDRS lines of BCVA. OCT
results were available for all 18 patients with CSME, the
mean central macular thickness was 487.4 mm (range
from 284 to 1082 mm), and decreased to a mean of
260.6mm (range from 178 to 475mm) at the end of follow-
up (Po0.0001). Final BCVA analysis by subgroups of
patients with CSME demonstrated that 14 eyes (82.4%)
improved two or more ETDRS lines of BCVA (Table 2).
Twenty-seven eyes (61.4%) showed total regression of
RN on fundus examination with absence of fluorescein
leakage (Figures 1 and 2), 15 eyes (34.1%) demonstrated
partial regression of RN on fundus examination and FA,
and two eyes (4.5%) of two patients showed no
regression of RN. The first of those two patients who did
not respond was treated with 1.25 mg of bevacizumab
and had PDR progression to tractional retinal
detachment requiring vitrectomy resulting in a poor final
visual acuity (VA) (counting fingers) due to ischaemic
optic neuropathy. The second patient was treated with
2.5 mg of bevacizumab and developed vitreous
haemorrhage with increased intraocular pressure
(ghost cell glaucoma). In addition, these two patients had
previous PRP (Table 3).
Twenty-one eyes (47.7%) needed a second injection
due to recurrence of neovascularization at a mean of
Figure 1 A 53-year-old man had a 2-month history of visual
loss to 20/60 in his right eye. We had performed panretinal
photocoagulation in his right eye 2 years previously. Fundus
examination revealed a mild vitreous haemorrhage. (a) Fluor-
escein leakage from neovascularization of the disc (NVD) at
baseline (arrow) between retinal vessels crossing the optic disc at
9 O’clock and 10 O’clock was demonstrated. In addition, FA
showed magnification of retinal neovascularization elsewhere
(NVE) in the superonasal retina (arrowheads). (b) At week 1
after intravitreal bevacizumab, total resolution of leakage from
NVD and NVE are shown. His VA returned to 20/32 1 month
later. He has not needed a reinjection at 5 months of follow-up.
Figure 2 (a) Late-phase fluorescein angiogram demonstrating
retinal neovascularization at the optic disc (NVD) (arrows) and
neovascularization elsewhere (NVE) (arrowheads) in an 80-year-
old man with proliferative diabetic retinopathy. He received a
complete panretinal photocoagulation 2 years previously. (b) A
fluorescein angiogram obtained 2 weeks after intravitreal
bevacizumab injection demonstrated total regression of leakage
from NVE and NVD in the late phase of the study.
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12.4 weeks (range from 4 to 34 weeks), and seven eyes
(15.9%) needed a third injection due to recurrence of
neovascularization at a mean of 17.3 weeks (range from
11 to 22 weeks). Three eyes without previous PRP (‘naive’
eyes) and with vitreous haemorrhage have avoided
vitreo-retinal surgery. There were no episodes of
inflammation or severe decrease of vision immediately
after an injection.
At 6 months, no systemic adverse events such as
thromboembolic events (cerebrovascular accidents,
transient ischaemic attacks, myocardial infarctions, or
peripheral vascular disease) were reported.
Discussion
Although RN actually may be due to more than one
cytokine, VEGF is an important, if not the most important
cytokine involved.25 Activation of the VEGF receptor
pathway triggers a network of signalling processes that
promotes endothelial cell growth, migration, survival from
pre-existing vessels, differentiation, and mobilization of
endothelial progenitor cells from the bone marrow into the
peripheral circulation.9,26,27 Furthermore, VEGF increases
vessel permeability leading to deposition of proteins in the
interstitium that facilitate the process of angiogenesis.28
There are several reports published on the intravitreal
administration of anti-VEGF compounds for RN in diabetic
retinopathy.7,13 In addition, there are five case reports on
the use of intravitreal bevacizumab in RN in diabetic
retinopathy demonstrating regression of RN in PDR.14,29–32
Our study demonstrated that intravitreal bevacizumab
resulted in marked regression of RN on fundus
examination and FA in patients with PDR and previous
PRP. Furthermore, a rapid resolution of vitreous
haemorrhage in three naive eyes was also seen. In
addition, intravitreal bevacizumab demonstrated a
similar beneficial response on macular thickness in eyes
with PDR, and probably bevacizumab prevents
exacerbation of macular oedema in patients with
concomitant CSME and PDR. To determine the effect of
an intravitreal injection of bevacizumab on actively
growing new vessels, we chose the change in vitreous
leakage from RN as our primary outcome. The detection
of NVD and NVE on FA allowed the use of a systematic
anatomical approach to monitor the area of leaking new
vessels over time. Finally, to determine the effect of an
intravitreal injection of bevacizumab on macular oedema,
we measured the change of retinal thickening with OCT.
Regression of neovascularization and decrease of
retinal thickening occurred in some injected eyes as soon
as 7–15 days after the intravitreal injection of
bevacizumab. Twenty-one eyes (47.7%) needed a second
injection due to recurrence of neovascularization at a
mean of 12.4 weeks, and seven eyes (15.9%) needed a
Table 1 Distribution of eyes according to prior treatment
Prior
treatment
2.5 mg IVT
bevacizumab
1.25 mg IVT
bevacizumab
Total of
eyes
PRP 12 2 14
PRPþgrid 11 4 15
PRPþ focal 2 2 4
Total of eyes 25 8 33
IVT, intravitreal; PRP, panretinal photocoagulation.
Table 2 Characteristics of patients with macular oedema associated to RN
Patient no. Prior treatment Baseline VA log Mar Baseline macular
thickness by OCT
(mm)
Final VA Log Mar Final macular
thickness by OCT
(mm)
1 PRP 0.3 284 0.1 244
4 No 1.0 1082 0.5 357
5 No 2.0 404 1.3 369
6 No 2.0 267 0.7 178
7 PRPþ focal 1.3 559 1.2 178
9 PRPþ grid 1.0 471 1.9 475
10 PRP 1.0 589 0.3 215
11 No 2.0 381 2.0 219
12 PRPþ grid 1.8 615 0.2 209
13 PRPþ grid 1.0 481 0.2 269
14 PRPþ grid 1.0 481 0.3 263
15 PRPþ grid 1.8 383 0.5 192
16 PRPþ grid 1.3 355 0.5 213
17 PRPþ grid 1.3 862 0.6 324
18 PRPþ grid 1.0 362 0.5 203
19 (RE) PRP 1.8 367 1.3 270
19 (LE) No 2.0 343 1.3 252
CF, counting fingers; LE, left eye; OCT, optical coherence tomography; PRP, panretinal photocoagulation; RE, right eye; RN, retinal neovascularization;
VA, visual acuity.
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third injection due to recurrence of neovascularization at
a mean of 17.3 weeks. Interestingly, we found that the
2.5 mg seems to be more effective than the 1.25 mg dose
to induce complete regression of RN in naive eyes
(P¼ 0.01; Table 3). The reason for this dose-dependant
response on RN in naive eyes in unknown. In addition,
the optimum dose and dosing sequence for intravitreal
bevacizumab is still undetermined. We elected to defer
reinjection only when there was a recurrence. Our clinical
impression is that the effect of intravitreal bevacizumab
on RN may be more lasting than in eyes with other
pathologies such as choroidal neovascularization or
macular oedema; however, the cause is not known.
Our results suggest an overall VA gain as well as a
reduced risk of VA loss in eyes with diabetic macular
oedema (as recognized on OCT) treated with intravitreal
bevacizumab. We did not find any differences in the
effectiveness between the doses of 1.25 and 2.5 mg for
CSME, both of them demonstrated improvement with
respect to VA and decrease in retinal thickness. Avery
et al13 reported similar results to the present study in
45 eyes of 32 patients with retinal and/or iris
neovascularization secondary to diabetes mellitus who
had received intravitreal injections of 6.2 mg–1.25 mg of
bevacizumab. They demonstrated that all patients with
neovascularization had complete or at least partial
reduction in leakage of the neovascularization within
1 week after the injection. Additionally, they found in
two cases, a subtle decrease in leakage of retinal or iris
neovascularization in the fellow uninjected eye. We could
not confirm their observation as in our study, utilizing
higher doses (1.25–2.5 mg) of bevacizumab, all of our
patients with bilateral RN underwent bilateral
intravitreal injections.
Panretinal photocoagulation has been the mainstay for
the treatment of PDR, and its suppressive effect on RN
has been well documented.20,21,33,34 However, substantial
regression of new vessels may take weeks after
completion of PRP, and in up to one-third of cases, new
vessels continue to grow despite initial PRP.21,34 In these
cases, vitreous haemorrhage may induce visual loss and
prevent complete laser. Moreover, macular oedema may
increase after PRP and cause transient or persistent
visual loss.35,36 Our study demonstrates multiple benefits
of intravitreal bevacizumab on PDR and in the future this
new option could be an adjuvant agent to PRP so that
more selective therapy may be applied. In addition,
bevacizumab may allow long intervals between PRP
sessions to avoid the development of macular oedema
and other complications.21–24
The current study has several limitations, including a
relatively small sample size and a relatively short
duration of follow-up. In addition, this study included
patients from five different centres and patients were
treated according to the discretion of the treating
physician. However, the large difference in the
quantitative morphologic outcomes and the trend
towards improvement in BCVA in injected eyes found at
6 months confirms our hypothesis that at least some eyes
with PDR, such as those with pre-existing macular
oedema or rapidly growing new vessels, may truly
benefit from intravitreal bevacizumab. In addition, we
can safely assume with a 95% confidence, that the true
rate of systemic complications is o9% in our study.37
In summary, intravitreal bevacizumab seems to be a
promising treatment for PDR, minimizing the risk for
exudative complications, progression of RN, vitreous
haemorrhage, and decreased vision caused by macular
oedema. Intravitreal bevacizumab may potentially be
used as an adjuvant agent to PRP for PDR. Although no
serious complications of intravitreal injection of
bevacizumab occurred in our series, further studies are
needed to assess the efficacy and safety of intravitreal
bevacizumab in the management of PDR.
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